



aTyr Pharma

aTyr Pharma, Inc. Announces Closing of Initial Public Offering

May 12, 2015

SAN DIEGO, May 12, 2015 /PRNewswire/ -- aTyr Pharma, Inc. ("aTyr"), today announced the closing of its initial public offering of 6,164,000 shares of its common stock at an initial public offering price of \$14.00 per share, before underwriting discounts, including 804,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. aTyr's common stock is listed on The NASDAQ Global Select Market under the ticker symbol "LIFE."

J.P. Morgan Securities LLC and Citigroup Global Markets Inc. acted as joint book-running managers for the offering. BMO Capital Markets Corp. acted as lead manager and William Blair & Company, L.L.C. acted as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on May 6, 2015. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at prospectus-eg_fi@jpmchase.com; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at prospectus@citi.com or by telephone at 800-831-9146.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

SOURCE aTyr Pharma, Inc.